Excision BioTherapeutics Announces Publication in Molecular Therapy Methods & Clinical Development Highlighting EBT-104 for the Treatment of HSV-1 Keratitis
14 août 2024 11h54 HE
|
Excision BioTherapeutics
- Treatment with EBT-104 led to complete elimination of viral shedding in 92% eyes of treated rabbits - Excision’s proprietary gene editing technology holds unique, curative potential to address the...
Excision BioTherapeutics Awarded a “Fierce 15” Biotech Company of 2024
05 août 2024 08h26 HE
|
Excision BioTherapeutics
Company Applying its Proprietary CRISPR Technology to Address Recurrent Infections in Herpes Simplex Keratitis (HSK)HSK is the Leading Cause of Corneal Blindness in the United States, With an...
Excision BioTherapeutics Announces Data from the Phase 1/2 Trial of EBT-101 in HIV And In Vivo Efficacy Data in Herpes Virus and Hepatitis B
13 mai 2024 08h00 HE
|
Excision BioTherapeutics
EBT-101 successfully met the primary endpoint of safety and secondary endpoint of biodistribution/immunogenicity in a Phase 1/2 study (EBT-101-001)EBT-104 successfully reduced Herpes Virus DNA and...
Excision BioTherapeutics to Present Positive Data from its HSV-1 Keratitis Program, EBT-104, at the ASGCT 2024 Annual Meeting
22 avr. 2024 16h31 HE
|
Excision BioTherapeutics
Oral presentation to discuss CRISPR-associated gene editing inactivating herpes virusTwo poster presentations highlight the potential of EBT-104 for the treatment of HSV-1 Keratitis, demonstrating...
Excision BioTherapeutics Announces Oral Presentation Highlighting Positive Data from its HBV Program, EBT-107, at the Upcoming ASGCT 2024 Annual Meeting
22 avr. 2024 16h30 HE
|
Excision BioTherapeutics
SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious...
Excision BioTherapeutics Announces Oral Presentation of Preclinical HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24, 2024
22 avr. 2024 08h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious...
Excision BioTherapeutics Announces Oral Presentation of HSV-1 Keratitis Data at CRISPRMED24 Conference on April 24 2024
16 avr. 2024 08h00 HE
|
Excision BioTherapeutics
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious...
Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
10 avr. 2024 08h00 HE
|
Excision BioTherapeutics
Excision to give three oral presentations and outline new data in three posters from preclinical programs for herpes keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV) as well as a...
Excision BioTherapeutics Presents Positive Interim Clinical Data from Ongoing Phase 1/2 Trial of EBT-101 for the Treatment of HIV at ESGCT 30th Annual Congress
25 oct. 2023 08h30 HE
|
Excision BioTherapeutics
Excision reported positive safety and biodistribution data to 48 weeks in the first-in-human Phase 1/2 clinical evaluation of EBT-101No serious adverse events or dose-limiting toxicities were seen in...
Excision BioTherapeutics Announces Presentation of Interim Clinical Data for EBT-101 in Latent HIV at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
19 oct. 2023 07h50 HE
|
Excision BioTherapeutics
SAN FRANCISCO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases,...